Which has better valuation & earnings, ZYME or PCVX?

Zymeworks has higher revenue and earnings than Vaxcyte. Zymeworks is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $81.26M 21.60 -$81.13M -$1.37 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is ZYME or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Vaxcyte's return on equity of -32.51% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -126.92% -37.97% -25.31% Vaxcyte N/A -32.51% -29.51%

Does the media refer more to ZYME or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Zymeworks. Vaxcyte's average media sentiment score of 0.25 beat Zymeworks' score of 0.17 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, IMVT or ZYME?

Zymeworks has higher revenue and earnings than Immunovant. Zymeworks is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Zymeworks $81.26M 21.60 -$81.13M -$1.37 N/A

Is IMVT or ZYME more profitable?

Immunovant has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Zymeworks -126.92% -37.97% -25.31%

Does the media favor IMVT or ZYME?

In the previous week, Immunovant and Immunovant both had 2 articles in the media. Immunovant's average media sentiment score of 1.19 beat Zymeworks' score of 0.17 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZYME or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for Zymeworks. Kymera Therapeutics' average media sentiment score of 1.18 beat Zymeworks' score of 0.17 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, LNTH or ZYME?

Lantheus has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.25 $233.56M $4.15 24.33 Zymeworks $81.26M 21.60 -$81.13M -$1.37 N/A

Is LNTH or ZYME more profitable?

Lantheus has a net margin of 18.05% compared to Zymeworks' net margin of -126.92%. Lantheus' return on equity of 29.32% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Zymeworks -126.92% -37.97% -25.31%

Does the media favor LNTH or ZYME?

In the previous week, Lantheus had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Zymeworks. Lantheus' average media sentiment score of 0.54 beat Zymeworks' score of 0.17 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ZYME or PTGX?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 2 mentions for Zymeworks. Protagonist Therapeutics' average media sentiment score of 0.64 beat Zymeworks' score of 0.17 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zymeworks (ZYME) Competitors

$24.04 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$24.15 +0.11 (+0.46%)

As of 08:46 AM Eastern

Compare

ZYME vs. PCVX, IMVT, KYMR, LNTH, and PTGX

Should you buy Zymeworks stock or one of its competitors? MarketBeat compares Zymeworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zymeworks include Vaxcyte (PCVX), Immunovant (IMVT), Kymera Therapeutics (KYMR), Lantheus (LNTH), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Zymeworks compare to Vaxcyte?

Zymeworks (NASDAQ:ZYME) and Vaxcyte (NASDAQ:PCVX) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Vaxcyte had 4 more articles in the media than Zymeworks. MarketBeat recorded 6 mentions for Vaxcyte and 2 mentions for Zymeworks. Vaxcyte's average media sentiment score of 0.25 beat Zymeworks' score of 0.17 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zymeworks presently has a consensus price target of $38.00, indicating a potential upside of 58.07%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 81.59%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Vaxcyte's return on equity of -32.51% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Vaxcyte	N/A	-32.51%	-29.51%

Zymeworks has higher revenue and earnings than Vaxcyte. Zymeworks is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$81.26M	21.60	-$81.13M	-$1.37	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Zymeworks and Vaxcyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Zymeworks has higher revenue and earnings than Immunovant. Zymeworks is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Zymeworks	$81.26M	21.60	-$81.13M	-$1.37	N/A

In the previous week, Immunovant and Immunovant both had 2 articles in the media. Immunovant's average media sentiment score of 1.19 beat Zymeworks' score of 0.17 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Zymeworks	-126.92%	-37.97%	-25.31%

Immunovant currently has a consensus price target of $37.33, suggesting a potential upside of 20.00%. Zymeworks has a consensus price target of $38.00, suggesting a potential upside of 58.07%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Zymeworks beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Kymera Therapeutics?

Zymeworks (NASDAQ:ZYME) and Kymera Therapeutics (NASDAQ:KYMR) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Zymeworks currently has a consensus price target of $38.00, indicating a potential upside of 58.07%. Kymera Therapeutics has a consensus price target of $118.10, indicating a potential upside of 59.31%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Zymeworks has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$81.26M	21.60	-$81.13M	-$1.37	N/A
Kymera Therapeutics	$51.48M	118.46	-$311.35M	-$3.57	N/A

Zymeworks has a net margin of -126.92% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Kymera Therapeutics had 3 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for Zymeworks. Kymera Therapeutics' average media sentiment score of 1.18 beat Zymeworks' score of 0.17 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Zymeworks on 9 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Lantheus had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Zymeworks. Lantheus' average media sentiment score of 0.54 beat Zymeworks' score of 0.17 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus currently has a consensus target price of $101.86, suggesting a potential upside of 0.87%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 58.07%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Lantheus has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.25	$233.56M	$4.15	24.33
Zymeworks	$81.26M	21.60	-$81.13M	-$1.37	N/A

Lantheus has a net margin of 18.05% compared to Zymeworks' net margin of -126.92%. Lantheus' return on equity of 29.32% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Zymeworks	-126.92%	-37.97%	-25.31%

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Zymeworks on 11 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Protagonist Therapeutics?

Zymeworks (NASDAQ:ZYME) and Protagonist Therapeutics (NASDAQ:PTGX) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Zymeworks. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 2 mentions for Zymeworks. Protagonist Therapeutics' average media sentiment score of 0.64 beat Zymeworks' score of 0.17 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$81.26M	21.60	-$81.13M	-$1.37	N/A
Protagonist Therapeutics	$74.06M	84.56	-$130.15M	-$1.81	N/A

Zymeworks presently has a consensus price target of $38.00, indicating a potential upside of 58.07%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 18.31%. Given Zymeworks' stronger consensus rating and higher possible upside, equities analysts plainly believe Zymeworks is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Zymeworks has a net margin of -126.92% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

Summary

Zymeworks beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.76B	$989.71M	$4.24B	$11.98B
Dividend Yield	N/A	4.84%	9.67%	5.55%
P/E Ratio	-17.55	1.48	21.75	23.62
Price / Sales	21.60	135.52	222.28	89.64
Price / Cash	N/A	20.06	46.51	37.25
Price / Book	6.70	7.88	27.48	6.66
Net Income	-$81.13M	-$4.04M	$119.60M	$337.72M
7 Day Performance	-2.04%	-2.28%	-3.66%	-3.74%
1 Month Performance	0.63%	5.28%	0.23%	0.95%
1 Year Performance	N/A	106.41%	11.93%	25.35%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	2.5265 of 5 stars	$24.04 flat	$38.00 +58.1%	N/A	$1.76B	$81.26M	N/A	460	Gap Up
PCVX Vaxcyte	2.8378 of 5 stars	$51.40 +0.7%	$86.00 +67.3%	+28.0%	$7.37B	N/A	N/A	160	Gap Up
IMVT Immunovant	2.6541 of 5 stars	$33.30 -0.6%	$37.33 +12.1%	+85.5%	$6.84B	N/A	N/A	120
KYMR Kymera Therapeutics	2.2766 of 5 stars	$81.42 0.0%	$118.10 +45.0%	+55.7%	$6.70B	$51.48M	N/A	170
LNTH Lantheus	2.1422 of 5 stars	$99.30 -0.3%	$101.86 +2.6%	+23.8%	$6.49B	$1.54B	23.93	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. PCVX, IMVT, KYMR, LNTH, and PTGX

How does Zymeworks compare to Vaxcyte?

Summary

How does Zymeworks compare to Immunovant?

Summary

How does Zymeworks compare to Kymera Therapeutics?

Summary

How does Zymeworks compare to Lantheus?

Summary

How does Zymeworks compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. PCVX, IMVT, KYMR, LNTH, and PTGX

How does Zymeworks compare to Vaxcyte?

Do insiders & institutionals believe in ZYME or PCVX?

Does the media refer more to ZYME or PCVX?

Do analysts prefer ZYME or PCVX?

Which has more risk and volatility, ZYME or PCVX?

Is ZYME or PCVX more profitable?

Which has better valuation & earnings, ZYME or PCVX?

Summary

How does Zymeworks compare to Immunovant?

Do insiders & institutionals hold more shares of IMVT or ZYME?

Which has more risk and volatility, IMVT or ZYME?

Which has stronger earnings & valuation, IMVT or ZYME?

Does the media favor IMVT or ZYME?

Is IMVT or ZYME more profitable?

Do analysts prefer IMVT or ZYME?

Summary

How does Zymeworks compare to Kymera Therapeutics?

Do analysts recommend ZYME or KYMR?

Which has stronger earnings and valuation, ZYME or KYMR?

Is ZYME or KYMR more profitable?

Do institutionals & insiders believe in ZYME or KYMR?

Does the media prefer ZYME or KYMR?

Which has more risk and volatility, ZYME or KYMR?

Summary

How does Zymeworks compare to Lantheus?

Does the media favor LNTH or ZYME?

Do analysts rate LNTH or ZYME?

Which has preferable earnings & valuation, LNTH or ZYME?

Is LNTH or ZYME more profitable?

Which has more risk and volatility, LNTH or ZYME?

Do institutionals and insiders hold more shares of LNTH or ZYME?

Summary

How does Zymeworks compare to Protagonist Therapeutics?

Do insiders and institutionals believe in ZYME or PTGX?

Does the media refer more to ZYME or PTGX?

Which has better valuation and earnings, ZYME or PTGX?

Do analysts recommend ZYME or PTGX?

Is ZYME or PTGX more profitable?

Which has more volatility & risk, ZYME or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools